AI Stock Memo: OLMA - Olema - RankAlpha

OLMA

Rating neutralAI Memo

Olema

As of 2026-04-15/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-04-15 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

6‑12m

Key catalyst

OP-3136 initial clinical data in Q2 2026 • 2026-06-30

Expected move: +48%

Biggest risk

This is still a low-coverage, clinical-stage biotech with negative deterministic priors, low catalyst density, and a thesis heavily concentrated in one pivotal readout; competitor programs listed by Olema itself suggest crowded ER+ breast-cancer development, and any weak OP-3136 signal or OPERA-01 slippage would likely hit the stock hard [#10-K-2026-03-16].

Invalidation

Break below $10 or thesis failure.

What would change my mind?

The constructive case is straightforward: the company has cash runway into mid-2028, OP-3136 data are due in Q2 2026, and the core equity unlock is OPERA-01 top-line data in fall 2026 with management already outlining a possible 2027 NDA and late-2027 launch path if the study works [#10-K-2026-03-16][#8-K-2026-03-16].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-04-15

Base target

$17

p=1%

Bull target

$26

p=0%

Bear target

$10

p=0%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Runway and execution window into late-stage milestones
The constructive case is straightforward: the company has cash runway into mid-2028, OP-3136 data are due in Q2 2026, and the core equity unlock is OPERA-01 top-line data in fall 2026 with management already outlining a possible 2027 NDA and late-2027 launch path if the study works [#10-K-2026-03-16][#8-K-2026-03-16].
At $16.30, OLMA trades far below the packet's median analyst target, but the discount is not enough on its own to justify a bullish call because valuation is mostly an option on clinical execution rather than current fundamentals.

BearKey bullets

Cash runway is projected through mid-2028, but higher trial/commercial-prep spending could pull financing needs forward if timelines slip.
Competitive ER+/HER2- metastatic breast-cancer programs may reach approval or stronger positioning ahead of palazestrant.
OP-3136 is early stage; disappointing initial data would reduce pipeline diversification and leave OLMA more single-asset dependent.

WatchKey bullets

OP-3136 initial clinical data in Q2 2026

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $17 (p=1%)

Bull/Bear spread: +127% / -13%

Vs latest close: Bull +127% · Base +48% · Bear -13%

Scenario probabilities

Bull Target: $26 (p=0%)Base Target: $17 (p=1%)Bear Target: $10 (p=0%)

Commentary

Overall sentiment is cautious-monitoring rather than bullish. Primary sources support a credible runway and a clear 2026 catalyst calendar, but forward visibility is still mostly binary and concentrated in palazestrant. The March 2026 sympathy selloff tied to an external breast-cancer readthrough reinforces how exposed OLMA is to sector and mechanism sentiment, not just its own data.

As of 2026-04-15 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Runway and execution window into late-stage milestones

Scenarios

Bull Target (Scenario probability)

$26 / p=0% prob

Base Target (Scenario probability)

$17 / p=1% prob

Bear Target (Scenario probability)

$10 / p=0% prob

Price $11 as of 2026-07-31

Nearest Scenario: Bear (∆ 13%)

Targets vs latest close: Bull +127% · Base +48% · Bear -13%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-06-30
OP-3136 initial clinical data in Q2 2026
Olema said initial clinical results from the Phase 1 OP-3136 study are expected in Q2 2026 at a major medical conference; this is the nearest true pipeline datapoint and could either validate a second asset or reinforce the view that OLMA remains mostly a palazestrant story [#8-K-2026-03-16].
Prob 65.00% • Move 18.00% • Priced-in 35.00%
EVENT2026-10-15
Pivotal OPERA-01 top-line data expected in fall 2026
Management and the 10-K point to fall 2026 top-line data from the pivotal Phase 3 OPERA-01 monotherapy trial in 2/3L ER+/HER2- metastatic breast cancer; this is the main value driver because the company also frames NDA submission in 2027 and potential approval/commercial launch in late 2027 if successful [#10-K-2026-03-16][#8-K-2026-03-16].
Prob 60.00% • Move 45.00% • Priced-in 45.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Runway and execution window into late-stage milestones
2028-06-30
Olema ended 2025 with $505.4 million in cash, cash equivalents, and marketable securities and says existing resources plus credit-facility availability should fund the current operating plan through mid-2028, which lowers near-term financing pressure while OPERA-01, OPERA-02, and OP-3136 advance [#10-K-2026-03-16][#8-K-2026-03-16].
Prob 75% • Move 12% • Priced-in 70%

Risks

Cash runway is projected through mid-2028, but higher trial/commercial-prep spending could pull financing needs forward if timelines slip.
Competitive ER+/HER2- metastatic breast-cancer programs may reach approval or stronger positioning ahead of palazestrant.
OP-3136 is early stage; disappointing initial data would reduce pipeline diversification and leave OLMA more single-asset dependent.
OPERA-01 is the dominant value driver, so weak efficacy, safety issues, or timing slippage could reset the equity sharply.

Peers

Symbol	Summary
ARVN	Arvinas is the closest public comparator because vepdegestrant is a competing ER-targeting program in ER+/HER2- metastatic breast cancer; Olema itself lists vepdegestrant as a competitive program in its 10-K.
AZN	AstraZeneca is a relevant large-cap breast-cancer comparator through camizestrant and marketed endocrine therapy exposure; Olema lists camizestrant and Faslodex-related competition in its 10-K.
LLY	Eli Lilly is relevant through imlunestrant/Inluriyo in ER+ breast cancer; Olema identifies imlunestrant as a competing product/program in its 10-K, underscoring the crowded endocrine-therapy landscape.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-04-15